

**IN THE CLAIMS:**

Please substitute the following listing of claims for the previous listing of claims:

1-37. (Cancelled)

38. (Currently amended) A pharmaceutical formulation for pulmonary administration, the pharmaceutical formulation comprising:

particulates comprising porous particles ~~consisting essentially of~~ active agent particles in a matrix comprising a phospholipid, the active agent particles having a geometric diameter of less than about 3  $\mu\text{m}$  and a solubility in water of about 0.1 to about 1.0 mg/ml and wherein the active agent particles are dispersed within the phospholipid matrix; and

wherein the particulates are porous, have a mass median diameter less than 20  $\mu\text{m}$ , a bulk density of less than about 0.5 g/cm<sup>3</sup>, a mass median aerodynamic diameter less than about 2.6  $\mu\text{m}$ , and wherein the particulates do not comprise lactose.

39. (Previously presented) A pharmaceutical formulation according to claim 38 wherein the formulation provides for the delivery to the lung of a dose of at least about 5 mg in a single inhalation.

40. (Cancelled)

41. (Previously presented) A pharmaceutical formulation according to claim 38 wherein a formulation fine particle fraction of less than 3.3  $\mu\text{m}$  is at least about 72 percent.

42-43. (Cancelled)

44. (Previously presented) A pharmaceutical formulation according to claim 38 wherein the matrix comprises one or more of dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, diarachidoylphosphatidylcholine, dibehenoylphosphatidylcholine, diphosphatidyl glycerol, short-chain phosphatidylcholines, long-chain saturated phosphatidylethanolamines, long-chain saturated phosphatidylserines, long-chain saturated phosphatidylglycerols, and long-chain saturated phosphatidylinositols.

45-46. (Cancelled)

47. (Original) A pharmaceutical formulation according to claim 38 wherein the particulates have a bulk density less than  $0.3 \text{ g/cm}^3$ .

48. (Original) A pharmaceutical formulation according to claim 38 wherein the particulates have a bulk density less than  $0.2 \text{ g/cm}^3$ .

49. (Original) A pharmaceutical formulation according to claim 38 wherein the particulates are in a dry powder form for aerosolization in a dry powder inhaler.

50. (Original) A pharmaceutical formulation according to claim 38 wherein the particulates are suspended in a propellant for aerosolization in a metered dose inhaler.

51. (Original) A pharmaceutical formulation according to claim 38 wherein the particulates are suspended within a liquid for aerosolization in a nebulizer.

52. (Original) A pharmaceutical formulation according to claim 38 wherein the particulates further comprise a polyvalent cation.

53. (Previously presented) A pharmaceutical formulation according to claim 38 wherein the particulates are formed by spray drying with a blowing agent.

54. (Currently amended) A pharmaceutical formulation for pulmonary administration, the pharmaceutical formulation comprising:  
particulates ~~comprising consisting essentially of~~ amphotericin B particles in a matrix comprising a phospholipid wherein the amphotericin B particles have a solubility in water of about 0.1 to about 1.0 mg/ml, and are dispersed within the phospholipid matrix, and;

wherein the particulates are porous, have a mass median diameter less than 20  $\mu\text{m}$ , a bulk density of less than about 0.5 g/cm<sup>3</sup> and a mass median aerodynamic diameter less than about 2.6  $\mu\text{m}$ , and wherein the particulates do not comprise lactose.

55. (Original) A pharmaceutical formulation according to claim 54 wherein the particulates have a mass median diameter less than 10  $\mu\text{m}$ .

56. (Original) A pharmaceutical formulation according to claim 54 wherein the particulates have a mass median diameter less than 5  $\mu\text{m}$ .

57. (Cancelled)

58. (Original) A pharmaceutical formulation according to claim 54 wherein the amphotericin B particles are crystalline.

59. (Cancelled)

60. (Previously presented) A pharmaceutical formulation according to claim 54 wherein the lipid matrix comprises one or more of dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, diarachidoylphosphatidylcholine, dibehenoylphosphatidylcholine, diphosphatidyl glycerol, short-chain phosphatidylcholines, long-chain saturated phosphatidylethanolamines, long-chain saturated phosphatidylserines, long-chain saturated phosphatidylglycerols, and long-chain saturated phosphatidylinositols.

61. (Cancelled)
62. (Original) A pharmaceutical formulation according to claim 54 wherein the particulates have a bulk density less than  $0.3 \text{ g/cm}^3$ .
63. (Original) A pharmaceutical formulation according to claim 54 wherein the particulates have a bulk density less than  $0.2 \text{ g/cm}^3$ .
64. (Original) A pharmaceutical formulation according to claim 54 wherein the particulates are in dry powder form for aerosolization in a dry powder inhaler.
65. (Original) A pharmaceutical formulation according to claim 54 wherein the particulates are suspended in a propellant for aerosolization in a metered dose inhaler.
66. (Original) A pharmaceutical formulation according to claim 54 wherein the particulates are suspended within a liquid for aerosolization in a nebulizer.
67. (Original) A pharmaceutical formulation according to claim 54 wherein the particulates further comprise a polyvalent cation.
68. (Original) A pharmaceutical formulation according to claim 54 wherein the particulates are formed by spray drying with a blowing agent.
- 69-102. (Cancelled).
103. (Previously presented) A pharmaceutical formulation according to claim 38 wherein the active agent comprises ciprofloxacin.

104. (Currently amended) A ~~particulate~~ pharmaceutical formulation in dry powder form for aerosolization and pulmonary administration, the pharmaceutical formulation comprising: which comprises

an active agent particle having a geometric diameter of less than about 3  $\mu\text{m}$  and ~~at least one property of~~ a solubility in water of about 0.1 to about 1.0 mg/ml, or a low glass transition temperature of, ~~which comprises~~ about 283°C;

a porous phospholipid material matrix ~~surrounding the active agent particle~~ wherein the active agent particle is substantially within the phospholipid matrix; and

wherein the ~~particulate~~ pharmaceutical formulation is formed by preparing a feedstock comprising ~~a suspension of the active agent particles and~~ one or more phospholipids ~~the phospholipid material~~, and spray-drying the feedstock to produce porous particulates having a mass median diameter less than 20  $\mu\text{m}$ , a bulk density of less than about 0.5 g/cm<sup>3</sup> and a mass median aerodynamic diameter less than about 2.6  $\mu\text{m}$ , and wherein the particulates do not comprise lactose.

105. (Currently amended) A ~~The~~ pharmaceutical formulation according to claim 104 wherein the particulates have a bulk density less than 0.3 g/cm<sup>3</sup>.

106-108. (Cancelled)

109. (New) A pharmaceutical formulation according to claim 38 wherein the particles consist essentially of the active agent.

110. (New) A pharmaceutical formulation according to claim 54 wherein the amphotericin B particles consist essentially of amphotericin B.

111. (New) A pharmaceutical formulation according to claim 104 wherein the active agent particles consist essentially of the active agent.